Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + cisplatin + 5-fluorouracil vs cisplatin + 5-fluorouracil as induction therapy in pediatric nasopharyngeal carcinoma
2007-001211-33Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel, cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sanofi. Primary endpoint: Complete response rate after induction treatment. Started Apr 2007; status: completed.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2007-001211-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001211-33.